Information  X 
Enter a valid email address

Company Name matching 'Galapagos NV'

Date
Time Source
Company
Announcement
17 Mar 2020 8:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos increases share capital through warrant exercises
20 Feb 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) Transformational year for Galapagos
29 Jan 2020 7:00 am GNW Factsheet Galapagos NV (GLPG) Orphan Drug Designation for GLPG1690 in systemic sclerosis
23 Jan 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos appoints Michele Manto as Chief Commercial Officer
15 Jan 2020 6:30 am GNW Factsheet Galapagos NV (GLPG) Fibrocor and Galapagos sign expanded collaboration in fibrosis
13 Jan 2020 6:30 am GNW Factsheet Galapagos NV (GLPG) Galapagos completes recruitment of PINTA trial in idiopathic pulmonary fibrosis
09 Jan 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos to present at 38th Annual J.P. Morgan Healthcare Conference
  9:01 pm GNW Factsheet Galapagos NV (GLPG) Gilead holds 25.84% of Galapagos shares
19 Dec 2019 9:30 pm GNW Factsheet Galapagos NV (GLPG) Gilead submits new drug application to U.S. Food and Drug Administration under priority review for filgotinib for rheumatoid arthritis treatment
05 Dec 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos completes recruitment of NOVESA trial in systemic sclerosis
25 Nov 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos increases share capital through warrant exercises
18 Nov 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos receives transparency notification from Wellington Management Group LLP
13 Nov 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Transparency notification – Gilead holds 25.10% of Galapagos shares
09 Nov 2019 9:30 pm GNW Factsheet Galapagos NV (GLPG) NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE
06 Nov 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos increases share capital through warrant exercise by Gilead
01 Nov 2019 8:01 pm GNW Factsheet Galapagos NV (GLPG) Gilead delivers exercise notice to Galapagos for Initial Warrant A to increase ownership to 25.1%
31 Oct 2019 8:01 pm GNW Factsheet Galapagos NV (GLPG) GILEAD AND GALAPAGOS TO PRESENT NEW DATA ON FILGOTINIB AT 2019 ACR/ARP ANNUAL MEETING
28 Oct 2019 8:45 pm GNW Factsheet Galapagos NV (GLPG) MOR106 clinical development in atopic dermatitis stopped for futility
25 Oct 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos receives transparency notification from Wellington Management Group LLP
24 Oct 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Solid third quarter 2019 performance with strong balance sheet for continued R&D growth
10 Oct 2019 11:00 pm GNW Factsheet Galapagos NV (GLPG) GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS
07 Oct 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos receives transparency notification from Wellington Management Group LLP
24 Sep 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos initiates Phase 1 trial for second Toledo compound
20 Sep 2019 9:53 pm GNW Factsheet Galapagos NV (GLPG) Invitation to the special and extraordinary shareholders' meetings
  9:01 pm GNW Factsheet Galapagos NV (GLPG) Invitation to the special and extraordinary shareholders' meetings
19 Sep 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Transparency notification
  9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos increases share capital through warrant exercises
30 Aug 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Transparency notification
28 Aug 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Transparency notification – Gilead holds 22% of Galapagos shares
23 Aug 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
15 Aug 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) EUROPEAN MEDICINES AGENCY VALIDATES MARKETING APPLICATION FOR FILGOTINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
25 Jul 2019 9:02 pm GNW Factsheet Galapagos NV (GLPG) Strong clinical progress in H1 and transformative collaboration with Gilead announced
18 Jul 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Transparency notification
14 Jul 2019 6:01 pm GNW Factsheet Galapagos NV (GLPG) GILEAD AND GALAPAGOS ENTER INTO TRANSFORMATIVE RESEARCH AND DEVELOPMENT COLLABORATION
02 Jul 2019 6:00 am GNW Factsheet Galapagos NV (GLPG) GILEAD ANNOUNCES INTENT TO SUBMIT NEW DRUG APPLICATION FOR FILGOTINIB TO U.S. FOOD AND DRUG ADMINISTRATION THIS YEAR
20 Jun 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos increases share capital through warrant exercises
17 Jun 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Transparency notification
11 Jun 2019 6:00 am GNW Factsheet Galapagos NV (GLPG) Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
29 May 2019 9:30 pm GNW Factsheet Galapagos NV (GLPG) GILEAD AND GALAPAGOS TO PRESENT LATEST DATA ON FILGOTINIB AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR 2019)
25 Apr 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos reports on historic first quarter 2019
23 Apr 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
10 Apr 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos creates new warrant plans
29 Mar 2019 9:15 pm GNW Factsheet Galapagos NV (GLPG) Publication of the annual report and invitation to the annual shareholders' meeting
28 Mar 2019 9:22 pm GNW Factsheet Galapagos NV (GLPG) GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)
  9:07 pm GNW Factsheet Galapagos NV (GLPG) GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)
  9:01 pm GNW Factsheet Galapagos NV (GLPG) GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY ENDPOINT IN THE PHASE 3 FINCH 3 STUDY IN METHOTREXATE-NAÏVE RHEUMATOID ARTHRITIS PATIENTS
  9:00 pm GNW Factsheet Galapagos NV (GLPG) GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 FINCH 1 RHEUMATOID ARTHRITIS STUDY
20 Mar 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos increases share capital through warrant exercises
21 Feb 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Firmly on our way to becoming a fully integrated biopharma company
07 Feb 2019 6:30 am GNW Factsheet Galapagos NV (GLPG) Evotec and Galapagos enter into collaboration in the field of fibrosis
08 Jan 2019 9:02 pm GNW Factsheet Galapagos NV (GLPG) Sands Capital reports 5.7% holding in Galapagos
07 Jan 2019 6:30 am GNW Factsheet Galapagos NV (GLPG) Galapagos starts first Phase 1 trial with Toledo compound
06 Jan 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis
04 Jan 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Fibrocor and Galapagos sign partnership in fibrosis
21 Dec 2018 9:02 pm GNW Factsheet Galapagos NV (GLPG) Galapagos to Present at 37th Annual J.P. Morgan Healthcare Conference
17 Dec 2018 9:19 pm GNW Factsheet Galapagos NV (GLPG) Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF)
27 Nov 2018 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis
26 Nov 2018 9:01 pm GNW Factsheet Galapagos NV (GLPG) Transparency notification
23 Nov 2018 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos increases share capital through warrant exercises
31 Oct 2018 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos reports initiation of PINTA Phase 2 trial with GLPG1205 in patients with Idiopathic Pulmonary Fibrosis (IPF)


Company Announcements Archive »


a d v e r t i s e m e n t